Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07313592 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment resumed after suspension Interventions modified · Site details revised · Eligibility criteria expanded, about 4 words Show 3 more changesShow less
    • Interventions modified
    • Site details revised
    • Eligibility criteria expanded, about 4 words
  2. Recruitment suspended Sponsor's reason: Admin review Site details revisedv5 Show 1 more changeShow less
    • Site details revised
  3. Recruitment opened Primary and study completion pushed from Jun 15, 2028 to Jul 15, 2028 · Start date changed from estimate of May 31, 2026 to Jun 3, 2026 · Site details revisedv4 Show 3 more changesShow less
    • Primary and study completion pushed from Jun 15, 2028 to Jul 15, 2028
    • Start date changed from estimate of May 31, 2026 to Jun 3, 2026
    • Site details revised
  4. Start date: Feb 28, 2026 to May 31, 2026 Primary and study completion pushed from Mar 15, 2028 to Jun 15, 2028v3 Show 1 more changeShow less
    • Primary and study completion pushed from Mar 15, 2028 to Jun 15, 2028
  5. Primary and study completion dates: Feb 15, 2028 to Mar 15, 2028 Start date: Jan 31, 2026 to Feb 28, 2026v2 Show 1 more changeShow less
    • Start date: Jan 31, 2026 to Feb 28, 2026
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective data collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young patients suspected of having ALL. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup as part of standard of care, and the patients will then be followed for clinical outcomes for up to 65 months.
Trial Details
NCT Number NCT07313592
Lead Sponsor Washington University School of Medicine
Collaborators: McDonnell Center
Conditions Acute Lymphoblastic Leukemia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov